Quality of Life in Migraine Patients: A Qualitative Study

Gendering the migraine market: Do representations of illness matter?

Migraine is a common, debilitating and costly disorder. Yet help-seeking for and rates of diagnosis of migraine are low. Drawing on ethnographic observations of pharmaceutical marketing practices at professional headache conferences and a content analysis of migraine advertising, principally in the USA, this paper demonstrates: (1) that the pharmaceutical industry directs its marketing of migraine medication to women; and (2) as part of this strategy, pharmaceutical advertisements portray women as the prototypical migraine sufferer, through representations that elicit hegemonic femininity. This strategy creates the impression that migraine is a "women's disorder", which, in turn, exacerbates gender bias in help seeking and diagnosis of migraine and reifies presumptions about the epidemiology of the disorder. I conclude that these pharmaceutical marketing practices have a paradoxical effect: even as they educate and raise awareness about migraine, they also create barriers to help seeking and diagnosis.

Population-based U.S. study of severe headaches in adults: psychological distress and comorbidities

OBJECTIVE

To examine the associations between severe headaches (SH), psychological distress, and comorbid conditions among U.S. adults.

BACKGROUND

The lifetime prevalence of headaches is over 90% and headaches, particularly migraines, have been associated with disability, increased healthcare costs, and mood disorders.

METHODS

We analyzed data obtained from adults aged 18 years or older (n = 29,828) who participated in the 2002 National Health Interview Survey, an ongoing, computer-assisted personal interview of a representative sample of the U.S. population.

RESULTS

Approximately 15.1% of adults aged 18 years or older reported SH in the previous 3 months. Those reporting such headaches were significantly more likely, than those who did not, to report insomnia, excessive sleepiness, recurrent pain, and depressive or anxiety symptoms during the preceding 12 months. Approximately 88% of those who reported having had SH within the previous 3 months also indicated that they had at least one comorbid medical condition, relative to 67% of those without SH.

CONCLUSION

Despite their episodic nature, our results suggest that SH are associated with impairments in both physical and mental health. As the presence of SH may serve as an indicator of significant psychological distress and medical comorbidities, eliciting information about their occurrence during a standard medical examination appears to be warranted.

Factors influencing migraineur-consulting behavior in a university population

OBJECTIVE

The purpose of this study was to identify factors that contribute to treatment-seeking behavior in migraineurs in a large employer population. Specifically, the impact of psychographic variables, such as social support, attitudes toward medication, locus of control, and migraine-associated disability, are considered concomitantly with demographic and disease severity variables.

BACKGROUND

Migraine remains an underconsulted condition. Previous explorations of demographic factors and headache characteristics have not adequately predicted migraineur physician-consulting behavior.

METHODS

University employees and students experiencing headaches were interviewed by pharmacists to determine whether they suffer from migraine using the International Headache Society (IHS) criteria for migraine. Identified migraineurs were categorized into 3 groups: (1) never-consulter, (2) lapsed-consulter, and (3) current-consulter. Each group was asked to complete an instrument that assesses perceived social support (Headache Social Support Questionnaire), medication attitudes (Beliefs about Medicines Questionnaire), locus of control (Headache-Specific Locus of Control Scale), and migraine-associated disability (Migraine Disability Assessment Questionnaire). Univariate (ANOVA) and multivariate (logistic regression) approaches were used to identify factors associated with migraineur-consulting behavior.

RESULTS

A total of 100 subjects participated in the study. Eighty-two participants met IHS criteria for migraine, of whom 22 were never-consulters, 20 were lapsed-consulters, and 40 were current-consulters. The consulter groups differed on scores acquired from the Social Support Active Involvement subscale (P= .04) and the Healthcare Professional Locus of Control subscale (P= .010). The logistic regression procedures confirmed the contributions of social support and healthcare locus of control in predicting migraineur-consulting behavior.

CONCLUSION

Results suggest that attitudes concerning the role of healthcare professionals and the presence of a supportive social network have greater influence on migraineur-consulting behavior than do patient demographic characteristics, beliefs about medications, and migraine frequency and severity. With an understanding of the link between psychosocial variables and consulting behavior, healthcare professionals may be able to positively impact migraineur physician consultation rates, drug therapy, and quality of life.

Experiences and perceptions of people with headache: a qualitative study

BACKGROUND

Few qualitative studies of headache have been conducted and as a result we have little in-depth understanding of the experiences and perceptions of people with headache. The aim of this paper was to explore the perceptions and experiences of individuals with headache and their experiences of associated healthcare and treatment.

METHODS

A qualitative study of individuals with headache, sampled from a population-based study of chronic pain was conducted in the North-East of Scotland, UK. Seventeen semi-structured interviews were conducted with adults aged 65 or less. Interviews were analysed using the Framework approach utilising thematic analysis.

RESULTS

Almost every participant reported that they were unable to function fully as a result of the nature and unpredictability of their headaches and this had caused disruption to their work, family life and social activities. Many also reported a negative impact on mood including feeling depressed, aggressive or embarrassed. Most participants had formed their own ideas about different aspects of their headache and several had searched for, or were seeking, increased understanding of their headache from a variety of sources. Many participants reported that their headaches caused them constant worry and anguish, and they were concerned that there was a serious underlying cause. A variety of methods were being used to manage headaches including conventional medication, complementary therapies and self-developed management techniques. Problems associated with all of these management strategies emerged.

CONCLUSION

Headache has wide-ranging adverse effects on individuals and is often accompanied by considerable worry. The development of new interventions or educational strategies aimed at reducing the burden of the disorder and associated anxiety are needed.

Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study

OBJECTIVE

To evaluate the impact of treatment with rizatriptan 10 mg on jobs and quality of life of patients with migraine.

METHODS

Prospective, open-label study at 27 work sites of 20 companies representing diverse labor sectors in Spain. Eligible patients according International Headache Society (IHS) criteria were recruited for the study by on-site physicians and instructed to treat moderate or severe migraine attacks with one tablet of rizatriptan 10 mg. They were asked to complete the study questionnaires (ML-96, SF-36) at baseline, and then 3 months later.

RESULTS

A total of 259 patients (83 men and 176 women) of a mean age of 39 (range 18 to 61 years) completed the study. Only 7% had taken triptans before for treatment of their migraine attacks. After 3 months of rizatriptan therapy, the use of medical services was significantly lower and all tested domains of quality of life had improved (P<.001). Absenteeism and days worked during migraine attacks also fell significantly during 3 months of rizatriptan therapy as compared with the 3 months before the study (P<.001). The improvement in productivity was reflected in the significant decreases in lost workday equivalents (decrease from 3.32 to 1.21 days; P<.001) and also in the total number of workdays lost (decrease from 5.16 to 1.82 days; P<.001). Two-thirds of patients described the efficacy of oral rizatriptan as excellent or very good (62%), and 89% preferred it over their usual medications for acute treatment of migraine attacks.

CONCLUSION

For this employed population of patients with migraine, treatment with rizatriptan significantly improved parameters measuring direct medical costs, work and productivity, and health-related quality of life. In accordance with these findings, direct and indirect costs related to migraine could be substantially reduced by gathering detailed information about the nature of headache, eliminating triggering factors, and instituting effective treatment of migraine attacks.

Aspirin is efficacious for the treatment of acute migraine

BACKGROUND

More than 50% of migraine sufferers rely on over-the-counter medications for the treatment of migraine. Along with other over-the-counter products, aspirin is considered by the US Headache Consortium to be an option for first-line migraine treatment. This study assessed the efficacy and tolerability of aspirin versus placebo for the acute treatment of a single acute attack of migraine.

METHODS

This prospective, randomized, double-blind, parallel-group, placebo-controlled study evaluated the efficacy of a single, 1000-mg dose of aspirin for the treatment of acute moderate to severe migraine, with or without aura. Subjects recorded all study evaluations in a diary at baseline and at .5, 1, 2, 3, 4, 5, 6, and 24 hours after treatment. Pain was rated on a 4-point ordinal scale from no pain to severe pain. The primary efficacy end point was headache response at 2 hours. Secondary efficacy parameters included reduction of nausea, photophobia and phonophobia, pain intensity difference, and headache recurrence at 24 hours.

RESULTS

Of 485 subjects enrolled, 409 took study medication and 401 treated a confirmed migraine attack (201 with aspirin and 200 with placebo). Baseline demographic and migraine characteristics were not significantly different between groups. The 2-hour headache response rate was 52% with aspirin versus 34% with placebo (P<.001). Aspirin was significantly more effective than placebo for pain reduction beginning 1 hour after dosing (P<.001) and continuing throughout the 6-hour evaluation period. Significantly (P<.05), more subjects were pain free from the 1-hour evaluation through the 6-hour evaluation. Of the aspirin-treated subjects, 20% were pain free at 2 hours versus only 6% of placebo-treated subjects. At 24 hours, the headache recurrence rate was 21.8% for aspirin (23 of 105 subjects) and 27.7% for placebo (19 of 68 subjects). Only 34% of aspirin-treated subjects needed rescue medication at 24 hours compared with 52% of placebo-treated subjects (P<.001). Aspirin was well tolerated, and adverse events were not significantly different between groups.

CONCLUSIONS

This study demonstrates that aspirin is safe and effective for treatment of acute migraine in appropriately selected patients.

The impact of migraine on psychological well-being of young women and their communication with physicians about migraine: a multinational study

OBJECTIVE

To describe the impact of migraine on psychological well-being of young women and to evaluate their communication with physicians about migraine.

RESEARCH DESIGN AND METHODS

This cross-sectional telephone survey was conducted in Israel and eight European countries (Finland, Germany, Greece, Italy, Norway, Spain, Sweden, and The Netherlands). Random-digit dialing was used to identify eligible study participants: women 18-35 years of age with migraine, who used medication to treat their migraine, and who were employed or full-time students.

RESULTS

Of 1810 participants, 42% self-reported having a physician diagnosis of migraine. Eighty-six per cent believed that their life would be better if they did not suffer from migraines; and 58% of participants felt frustrated, 46% felt angry, and 44% felt depressed because of their migraines. Negative feelings related to migraine varied substantially from country to country. For example, feelings of frustration caused by migraine ranged from 32% in Italy to 84% in Finland; feelings of anxiety ranged from 21% in Norway to 57% in Italy; and feelings of confusion ranged from 13% in Greece to 61% in Italy. Overall, 81% of participants had visited a physician in the past year but only 50% of them had discussed their severe headaches or migraines with their physician within the year. While 68% of those who had visited a physician stated that they were comfortable speaking with their physician about migraine, 71% reported being the one who initiated the conversation about severe headaches or migraines. Of all participants, 39% did not feel that their physician understood how much severe headaches or migraines interfered with their life.

CONCLUSIONS

Migraines and severe headaches impose a substantial burden on the psychological well-being of young women with migraine in Europe and Israel. In general, communication between these women and their physicians about migraine is incomplete.

Calcitonin gene-related peptide and its role in migraine pathophysiology

Migraine is a common neurological disorder that is associated with an increase in plasma calcitonin gene-related peptide (CGRP) levels. CGRP, a neuropeptide released from activated trigeminal sensory nerves, dilates intracranial blood vessels and transmits vascular nociception. Therefore, it is propounded that: (i) CGRP may have an important role in migraine pathophysiology, and (ii) inhibition of trigeminal CGRP release or CGRP-induced cranial vasodilatation may abort migraine. In this regard, triptans ameliorate migraine headache primarily by constricting the dilated cranial blood vessels and by inhibiting the trigeminal CGRP release. In order to explore the potential role of CGRP in migraine pathophysiology, the advent of a selective CGRP receptor antagonist was obligatory. The introduction of di-peptide CGRP receptor antagonists, namely BIBN4096BS (1-piperidinecarboxamide, N-[2-[[5-amino-1-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl] pentyl] amino]-1-[(3,5-dibromo-4-hydroxyphenyl) methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, [R-(R*,S*)]-), is a breakthrough in CGRP receptor pharmacology and can be used as a tool to investigate the role of CGRP in migraine headaches. Preclinical investigations in established migraine models that are predictive of antimigraine activity have shown that BIBN4096BS is a potent CGRP receptor antagonist and that it has antimigraine potential. Indeed, a recently published clinical study has reported that BIBN409BS is effective in treating acute migraine attacks without significant side effects. The present review will discuss mainly the potential role of CGRP in the pathophysiology of migraine and the various treatment modalities that are currently available to target this neuropeptide.